Lymphoid Cancer Research

What We Do

Our main research focus is to improve patient outcomes by gaining deeper understanding of lymphoma biology and disease progression which can be translated into clinical applications. Our ultimate goal is to improve patient outcomes through enhanced precision medicine, which can be designed using advanced genomic tools.

News & Events

Dr. David Scott named to Lymphoma Research Foundation scientific advisory board

The Lymphoma Research Foundation (LRF) is the largest non-profit lymphoma research organization in North America with a volunteer scientific advisory board comprised of world-renowned lymphoma experts, including Dr. David Scott. Dr. Scott is the clinical director of the BC Cancer Centre for Lymphoid Cancer, deputy head of the BC Cancer Lymphoid Cancer Research and an associate professor at the University of British Columbia. Dr.

More Info about Dr. David Scott named to Lymphoma Research Foundation scientific advisory board

BC Cancer researchers uncover therapeutically exploitable gene mutation in B-cell lymphoma

This understanding may be applicable to other cancer types in the future.

More Info about BC Cancer researchers uncover therapeutically exploitable gene mutation in B-cell lymphoma

Dr. Christian Steidl receives the Allen Distinguished Investigator Award

The research director of the Centre for Lymphoid Cancer at BC Cancer is the first Canadian recipient.

More Info about Dr. Christian Steidl receives the Allen Distinguished Investigator Award

New discovery reveals how Hodgkin lymphoma avoids attack from immune cells

BC Cancer researchers with the Centre for Lymphoid Cancer have discovered key information about how Hodgkin lymphoma can grow undetected within the body.

More Info about New discovery reveals how Hodgkin lymphoma avoids attack from immune cells

View all news

Research Labs & Principal Investigators

Scott Lab

Steidl Lab

Venturutti Lab

Recent Publications

Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis

Oncogene, 2016

Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, Inurrigarro G, Pereyra MG, Proietti CJ, Izzo F, Díaz Flaqué MC, Sundblad V, Roa JC, Guzmán P, Bal de Kier Joffé ED, Charreau EH, Schillaci R, Elizalde PV

Learn More

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

Oncogene, 2016

Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV

Learn More

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response

Cancer Cell, 2020

Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J, Camarillo JM, Takata K, Tarte K, Kelleher NL, Steidl C, Mason CE, Elemento O, Allis CD, Kleinstein SH, Melnick AM

Learn More